KR102232154B1 - (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 - Google Patents

(+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 Download PDF

Info

Publication number
KR102232154B1
KR102232154B1 KR1020197030218A KR20197030218A KR102232154B1 KR 102232154 B1 KR102232154 B1 KR 102232154B1 KR 1020197030218 A KR1020197030218 A KR 1020197030218A KR 20197030218 A KR20197030218 A KR 20197030218A KR 102232154 B1 KR102232154 B1 KR 102232154B1
Authority
KR
South Korea
Prior art keywords
weight
amount
coating formulation
pharmaceutical composition
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197030218A
Other languages
English (en)
Korean (ko)
Other versions
KR20190120418A (ko
Inventor
스리니바스 에스. 바트
마이클 티. 켈리
Original Assignee
암젠 (유럽) 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102232154(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 암젠 (유럽) 게엠베하 filed Critical 암젠 (유럽) 게엠베하
Publication of KR20190120418A publication Critical patent/KR20190120418A/ko
Application granted granted Critical
Publication of KR102232154B1 publication Critical patent/KR102232154B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
KR1020197030218A 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 Active KR102232154B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580626P 2011-12-27 2011-12-27
US61/580,626 2011-12-27
PCT/US2012/071623 WO2013101810A1 (en) 2011-12-27 2012-12-26 Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147020953A Division KR102035362B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008170A Division KR20210033073A (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Publications (2)

Publication Number Publication Date
KR20190120418A KR20190120418A (ko) 2019-10-23
KR102232154B1 true KR102232154B1 (ko) 2021-03-25

Family

ID=47459206

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197030218A Active KR102232154B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
KR1020217008170A Ceased KR20210033073A (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
KR1020147020953A Active KR102035362B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217008170A Ceased KR20210033073A (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
KR1020147020953A Active KR102035362B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Country Status (34)

Country Link
US (2) US20130164376A1 (enExample)
EP (3) EP4623993A3 (enExample)
JP (1) JP6161629B2 (enExample)
KR (3) KR102232154B1 (enExample)
CN (1) CN104136003A (enExample)
AU (1) AU2012362562B2 (enExample)
BR (1) BR112014015923B1 (enExample)
CA (1) CA2861594A1 (enExample)
CL (1) CL2014001726A1 (enExample)
CO (1) CO7000777A2 (enExample)
CR (1) CR20140314A (enExample)
CY (1) CY1123174T1 (enExample)
DK (2) DK2797581T3 (enExample)
EA (1) EA027801B1 (enExample)
EC (1) ECSP14007965A (enExample)
ES (2) ES3049175T3 (enExample)
FI (1) FI3756650T3 (enExample)
HR (2) HRP20251291T1 (enExample)
HU (1) HUE050327T2 (enExample)
IL (1) IL233296B (enExample)
LT (2) LT2797581T (enExample)
MX (2) MX373934B (enExample)
NI (1) NI201400068A (enExample)
PE (1) PE20142318A1 (enExample)
PH (1) PH12014501495B1 (enExample)
PL (1) PL2797581T3 (enExample)
PT (2) PT3756650T (enExample)
RS (2) RS60415B1 (enExample)
SG (2) SG11201403564YA (enExample)
SI (1) SI2797581T1 (enExample)
SM (2) SMT202000339T1 (enExample)
UA (1) UA113750C2 (enExample)
WO (1) WO2013101810A1 (enExample)
ZA (1) ZA201404629B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2627471C2 (ru) 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP3174999A1 (en) 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
MX377955B (es) * 2015-06-30 2025-03-10 Genentech Inc Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
CZ20165A3 (cs) * 2016-01-06 2017-07-19 Zentiva, K.S. Způsoby přípravy amorfního apremilastu
CN109310624A (zh) 2016-06-15 2019-02-05 托伦特药物有限公司 阿普斯特的局部组合物
IL287665A (en) * 2019-04-30 2022-07-01 Celgene Corp Combined treatments including apremilaste and tyk2 inhibitors
ES2823927B2 (es) * 2019-11-07 2022-01-18 Beijing Enbiwo Biological Tech Co Ltd Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales
KR20220047105A (ko) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 아프레밀라스트를 함유하는 약학 조성물
CN112245403B (zh) * 2020-10-23 2022-04-22 杭州朱养心药业有限公司 磷酸二酯酶-4抑制剂及其口服固体组合物
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023118043A1 (en) 2021-12-22 2023-06-29 Biohorm, S.L. Pharmaceutical compositions of apremilast

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
HUP0203682A3 (en) * 1999-10-29 2003-10-28 Smithkline Beecham Plc Method for administering a phosphodiesterase 4 inhibitor
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
AU2002343220A1 (en) 2001-11-09 2003-05-19 Matsushita Electric Industrial Co., Ltd. Moving picture coding method and apparatus
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0417186A (pt) 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
NZ550026A (en) 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
KR20070010184A (ko) 2004-04-23 2007-01-22 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
EP1814543A2 (en) 2004-11-12 2007-08-08 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
CA2588597A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
JP5775245B2 (ja) 2004-12-01 2015-09-09 セルジーン コーポレイション 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物
US20060183766A1 (en) * 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
EP1858514B1 (en) * 2005-03-17 2014-11-26 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2006111980A2 (en) 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
HRP20110348T1 (hr) 2005-09-01 2011-07-31 Celgene Corporation Imunološke primjene imunomodulatornih spojeva za cjepivo i za liječenje infektivnih bolesti
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
KR20150038547A (ko) * 2008-03-27 2015-04-08 셀진 코포레이션 (+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2196465A1 (en) * 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
MY160002A (en) 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
WO2011060290A2 (en) 2009-11-13 2011-05-19 Bristol-Myer Squibb Company Immediate release tablet formulations
CN103442698B (zh) * 2010-12-16 2016-10-05 细胞基因公司 难溶性药物的控释口服剂量形式及其用途
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Also Published As

Publication number Publication date
CN104136003A (zh) 2014-11-05
EP4623993A2 (en) 2025-10-01
KR20190120418A (ko) 2019-10-23
IL233296A0 (en) 2014-08-31
SI2797581T1 (sl) 2020-08-31
AU2012362562B2 (en) 2017-11-02
KR20210033073A (ko) 2021-03-25
KR20140108707A (ko) 2014-09-12
HK1202056A1 (en) 2015-09-18
ES2799448T3 (es) 2020-12-17
US20210093573A1 (en) 2021-04-01
HUE050327T2 (hu) 2020-11-30
BR112014015923B1 (pt) 2022-02-01
PT3756650T (pt) 2025-10-28
US20130164376A1 (en) 2013-06-27
JP2015506356A (ja) 2015-03-02
CY1123174T1 (el) 2021-10-29
ES3049175T3 (en) 2025-12-15
NI201400068A (es) 2016-01-28
KR102035362B1 (ko) 2019-10-22
SG11201403564YA (en) 2014-07-30
JP6161629B2 (ja) 2017-07-12
PT2797581T (pt) 2020-06-18
SG10201605251VA (en) 2016-08-30
BR112014015923A2 (pt) 2017-06-13
RS67339B1 (sr) 2025-11-28
CO7000777A2 (es) 2014-07-21
NZ626615A (en) 2016-08-26
DK3756650T3 (da) 2025-11-03
UA113750C2 (xx) 2017-03-10
PL2797581T3 (pl) 2020-10-05
MX2020005145A (es) 2020-08-17
FI3756650T3 (fi) 2025-10-30
EP3756650A1 (en) 2020-12-30
EP2797581A1 (en) 2014-11-05
EP3756650B1 (en) 2025-08-20
SMT202000339T1 (it) 2020-07-08
WO2013101810A1 (en) 2013-07-04
PH12014501495A1 (en) 2014-09-22
PE20142318A1 (es) 2015-01-16
RS60415B1 (sr) 2020-07-31
DK2797581T3 (da) 2020-07-20
EP2797581B1 (en) 2020-05-06
EA027801B1 (ru) 2017-09-29
ZA201404629B (en) 2017-08-30
IL233296B (en) 2018-11-29
ECSP14007965A (es) 2015-11-30
CL2014001726A1 (es) 2014-11-14
MX2014007878A (es) 2015-03-23
AU2012362562A1 (en) 2014-07-17
EA201491292A1 (ru) 2014-11-28
CR20140314A (es) 2014-10-28
LT2797581T (lt) 2020-07-10
CA2861594A1 (en) 2013-07-04
HRP20251291T1 (hr) 2025-12-05
EP4623993A3 (en) 2025-12-17
BR112014015923A8 (pt) 2017-07-04
PH12014501495B1 (en) 2014-09-22
LT3756650T (lt) 2025-11-10
SMT202500402T1 (it) 2025-11-10
HRP20200825T1 (hr) 2020-08-07
MX373934B (es) 2020-07-10

Similar Documents

Publication Publication Date Title
KR102232154B1 (ko) (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
JP5752677B2 (ja) ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオンの製剤
JP6339251B2 (ja) シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
AU2016213879B2 (en) Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
HK40042486A (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
HK1200356B (en) Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
HK1202056B (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
NZ626615B2 (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191015

Application number text: 1020147020953

Filing date: 20140725

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200203

Patent event code: PE09021S01D

PN2301 Change of applicant

Patent event date: 20200828

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201221

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210318

Application number text: 1020147020953

Filing date: 20140725

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210319

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210319

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Decision date: 20221123

Request date: 20210720

Appeal identifier: 2021100002208

Appeal kind category: Confirmation of the scope of right_defensive

Patent event code: PJ02062R01D

Patent event date: 20210720

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20210319

Comment text: Registration of Establishment

Decision date: 20221123

Request date: 20210720

Appeal identifier: 2021100002207

Appeal kind category: Confirmation of the scope of right_defensive

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Request date: 20210730

Appeal identifier: 2021100002341

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20221209

Request date: 20210730

Appeal identifier: 2021100002340

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Appeal identifier: 2021100002332

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Appeal identifier: 2021100002331

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20221130

Request date: 20210730

Appeal identifier: 2021100002320

Appeal kind category: Confirmation of the scope of right_defensive

Patent event code: PJ02062R01D

Patent event date: 20210730

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20210319

Comment text: Registration of Establishment

Decision date: 20220621

Request date: 20210730

Appeal identifier: 2021100002319

Appeal kind category: Confirmation of the scope of right_defensive

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20220621

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2021100002319

Request date: 20210730

Appeal kind category: Confirmation of the scope of right_defensive

Decision date: 20220621

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002208; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210720

Effective date: 20221123

Free format text: TRIAL NUMBER: 2021100002207; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210720

Effective date: 20221123

PJ1301 Trial decision

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210720

Decision date: 20221123

Appeal identifier: 2021100002208

Patent event code: PJ13011S02D

Patent event date: 20221123

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210720

Decision date: 20221123

Appeal identifier: 2021100002207

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002320; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210730

Effective date: 20221130

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20221130

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Decision date: 20221130

Appeal identifier: 2021100002320

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002340; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210730

Effective date: 20221209

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20221209

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Decision date: 20221209

Appeal identifier: 2021100002340

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002341; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210730

Effective date: 20221223

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20221223

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Decision date: 20221223

Appeal identifier: 2021100002341

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002331; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210730

Effective date: 20230201

PJ1301 Trial decision

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Decision date: 20230201

Appeal identifier: 2021100002332

Patent event code: PJ13011S02D

Patent event date: 20230201

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_defensive

Request date: 20210730

Decision date: 20230201

Appeal identifier: 2021100002331

PR1001 Payment of annual fee

Payment date: 20240226

Start annual number: 4

End annual number: 4